Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A.
about
Treatment for preventing bleeding in people with haemophilia or other congenital bleeding disorders undergoing surgeryTreatment for preventing bleeding in people with congenital bleeding disorders undergoing surgeryIncreased prevalence of inhibitors in Hispanic patients with severe haemophilia A enrolled in the Universal Data Collection database.Platelets as delivery systems for disease treatmentsMild hemophilia A.PEGylation of a factor VIII-phosphatidylinositol complex: pharmacokinetics and immunogenicity in hemophilia A mice.Inhibitors in haemophilia: clinical aspects.Inhibitors in congenital coagulation disorders.Therapy for haemophilia: recent advances and goals for the future.Retrospective audit of a continuous infusion protocol for haemophilia A at a single haemophilia treatment centre.Case studies: orthopaedic surgery in adult patients with haemophilia A with inhibitors.Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia.The need for previously untreated patient population studies in understanding the development of factor VIII inhibitors.Basic aspects of inhibitors to factors VIII and IX and the influence of non-genetic risk factors.The epidemiology of factor VIII inhibitors.Characteristics of inhibitors in mild/moderate haemophilia A.Mild/moderate haemophilia A: new insights into molecular mechanisms and inhibitor development.Low-dose continuous infusion of factor VIII in patients with haemophilia A.Inhibitors in mild/moderate haemophilia A: two case reports and a literature review.Risk factors for inhibitor formation in haemophilia: a prevalent case-control study.Secondary prophylaxis with factor IX concentrates: continuous infusion.Plasma exchange and immunosuppressive therapy in a case of mild haemophilia A with inhibitors and a life-threatening lower limb haemorrhage.Joint protection in haemophilia.Surgery and inhibitor development in hemophilia A: a systematic review.Evolution of the European guidelines for the clinical development of factor VIII products: little progress towards improved patient management.Inhibitors in childhood hemophilia A: genetic and treatment-related risk factors for development and eradication.Factor VIII inhibitors in hemophilia A: rationale and latest evidenceInhibitors - genetic and environmental factors.Molecular and clinical predictors of inhibitor risk and its prevention and treatment in mild hemophilia A.Intensity of factor VIII treatment and the development of inhibitors in non-severe hemophilia A patients: results of the INSIGHT case-control study.A close insight to factor VIII inhibitor in the congenital hemophilia A.Outcomes in Patients With Hemophilia and von Willebrand Disease Undergoing Invasive or Surgical Procedures.Incidence of low-titre factor VIII inhibitors in patients with haemophilia A: meta-analysis of observational studies.Therapeutic Apheresis in Hematologic, Autoimmune and Dermatologic Diseases With Immunologic Origin.Treatment burden, haemostatic strategies and real world inhibitor screening practice in non-severe haemophilia A.In non-severe hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: a case-control study.Retrospective analysis of in vivo recovery and clearance during continuous infusion of recombinant factor VIII products: a single-institution study.Biomimetic biosensor to distinguish between inhibitory and non-inhibitory factor VIII antibodies.Continuous infusion of factor concentrates in children with haemophilia A in comparison with bolus injections.Case studies in the management of refractory bleeding in patients with haemophilia A and inhibitors.
P2860
Q24188177-19B0C011-D373-4469-8EF8-63C5A1CE2EE5Q24202459-34B3B6B3-CB15-484D-BB4B-89B06D2022B3Q34129239-219EE901-8C8F-4E6E-B841-E0A94A616BC6Q34348837-D3E58927-1840-4E58-8092-2E9611DF1379Q34614695-037A1CE0-1F37-48F6-9AFA-A26C1350C14AQ35793113-36E6CAE9-EF62-4D0F-B4C5-BD1297827289Q35915717-532F865A-2EF5-422C-865B-FEA55DA42B24Q35937076-B87CA52C-2655-47C4-88DD-DB9D520AED9FQ36066048-B467295B-708D-4C1F-A9D7-2793C001189BQ36117527-41A859E7-451D-48B6-A15D-C4AEE47997A0Q36283856-6277F2AD-B368-41C9-AA1C-9B1E5DBA42FFQ36473047-4EA58866-A518-4599-B74A-884A9FE7811BQ36643861-8DBE1727-3D03-4769-AEA2-772D5140D79DQ36661807-17322239-E289-4D9E-9920-C95AA0CEE8D6Q36661815-40D871AB-565D-4192-9AF7-911ACD69D67FQ36661826-3789F24C-3E91-44BB-9462-D21DD0626112Q37176534-CFB76BF9-290C-4A13-BB11-A190B7950A32Q37242666-056BBCF4-377D-4924-B0A3-DD24D50576AAQ37244126-3F9C1F34-4172-41A3-A87D-95095B2ADC42Q37325682-0E7D6976-CC7C-4B1B-8050-340D4D5E597CQ37357215-41461B77-FEF6-4F7D-B794-763DE8AE7390Q37588914-16BA47C7-FE46-479F-B8AF-1D0AB045E0E8Q37912258-4466C10D-F1DC-4A4E-ACFC-34B11662ED1EQ37916686-6ECE60E3-ABD7-4044-9246-F23790227C36Q38054148-5D4D5F29-A596-4AE9-B6EF-3FD613F91D91Q38056462-60B910E8-410C-4AB5-942E-CFE2CE48E647Q38101041-8BDBA0F3-00C2-4FB8-8A7C-74C493EBEB2CQ38206856-6B22B7C5-A3B3-4381-A760-B3E09E5C0952Q38241445-09F06CDD-BE7C-40DC-A9EA-FCF2420BBCBCQ38691244-90232ABB-44D7-4081-8877-E9D5CD69ED25Q38883211-F02AD18D-6CD3-4352-B4B4-B64EDFDC0F4BQ38897517-C13F289F-17C4-4470-B300-B82DC1EDD364Q38950767-04869706-8561-4B5A-8362-A251AE4CBEBEQ38955520-CEA31F18-25E5-4397-84B3-7FD52FE49D0EQ38960476-1BD8D4A8-6331-4017-905E-6FA3417EF4E6Q39463597-2AB4D944-26F3-472F-969D-52B549859589Q40553769-A38FF9D5-F850-4B14-AA0A-DFB222535810Q40957193-34311A87-4D9B-46DA-B73D-869C99957A53Q42684126-39DF3FC6-F01A-4778-8922-0BBA928D4012Q44211358-1F429B53-CC2A-421E-8FCA-2995E7961C70
P2860
Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Intensive exposure to factor V ...... elopment in mild hemophilia A.
@ast
Intensive exposure to factor V ...... elopment in mild hemophilia A.
@en
type
label
Intensive exposure to factor V ...... elopment in mild hemophilia A.
@ast
Intensive exposure to factor V ...... elopment in mild hemophilia A.
@en
prefLabel
Intensive exposure to factor V ...... elopment in mild hemophilia A.
@ast
Intensive exposure to factor V ...... elopment in mild hemophilia A.
@en
P2093
P2860
P921
P1476
Intensive exposure to factor V ...... elopment in mild hemophilia A.
@en
P2093
Blanchette VS
Lillicrap D
Sharathkumar A
P2860
P304
P356
10.1046/J.1538-7836.2003.00230.X
P577
2003-06-01T00:00:00Z